This week, we will discuss intermittent hemodialysis versus continuous hemodialysis for AKI in the ICU (ICRAKI study)
Day 3 : yet another IgA trial, and we are back with some flozin news: in ADPKD, their effect on hemoglobin, and on BP (with finerenone)
Day 2 was less exciting: we cover 1 IgA trial (Ravulizumab) along with another calcimimetic, and a pentoxifylline meta-analysis.
Day of Kidney Week 2026. The NephJC crew discusses 6 studies, including some blockbustr IgA news.
This week, we will discuss whether decreased donor transplantation improves mortality in all patients. In this target trial emulation standard donor, extended donor, donation after brain death and donation after cardiac death outcomes are compared across age groups with different co-morbid conditions.
Tissue sodium excess is not hypertonic and reflects extracellular volume expansion (Rossitto, Nature Communications 2020)
Apart from the storify and transcript, don't miss the commentary from Rodby, and this summary from Paul Welling:
#nephjc A few final thoughts: pic.twitter.com/XdUZK1Z5K0
— Paul A Welling (@PaulAWelling1) June 7, 2017
